Wet Macular Degeneration Clinical Trial
Official title:
Non-Persistence/Non-Adherence of German wAMD Patients Related to Their Anti-VEGF Injections: Extent, Explanations and Patients' Preferences
In the research study an observation of patients with wet age-related macular degeneration
(wet AMD) will be performed.
The term observational study indicates that the current course of therapy and the associated
circumstances will be recorded. In this study, no medical care is changed. Also, no new
drugs are tested.
This study is being conducted in about 30 centers in Germany. A total of approximately 500
patients will be enrolled. The study is designed for a period of 12 months.
At the beginning and end of the study the physician will document the patient data.
Therefore will be used information from the patient records and documented visits. If such
information is not available in the study center, the otherwise attending ophthalmologist
will be consulted about the vision acuity values and visits in the observation period.
Furthermore, patients are asked to participate in three telephone interviews and fill out
during their visits to the study center a short questionnaire about their current vision and
their well-being. In the telephone interviews will be discussed with the patient about his
wet AMD disease and its treatment, its experience and its perspectives as well as any
problems occur.
n/a
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04049266 -
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
|
Phase 2/Phase 3 | |
Recruiting |
NCT01521065 -
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
|
Phase 2 | |
Terminated |
NCT05038371 -
Connective Tissue Growth Factor in Patients With Neovascular Age Related Macular Degeneration
|
||
Completed |
NCT03278262 -
The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting
|
||
Completed |
NCT04982484 -
Reading Speed Improvements in Wet-AMD Patients After Ranibizumab Treatment
|
||
Completed |
NCT00590694 -
Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments
|
Phase 2/Phase 3 | |
Completed |
NCT04516278 -
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
|
Phase 3 | |
Completed |
NCT03844074 -
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
|
Phase 3 | |
Recruiting |
NCT05637255 -
A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)
|
Phase 2 | |
Completed |
NCT04756310 -
Study of Nutritional Supplementation in Patients With Unilateral Wet AMD
|
N/A | |
Active, not recruiting |
NCT05112861 -
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
|
Phase 3 | |
Enrolling by invitation |
NCT03999801 -
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
|
Phase 2 | |
Terminated |
NCT03699618 -
Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration
|
||
Completed |
NCT01666821 -
A Population-based Study of Macular Choroidal Neovascularization in a Chinese Population
|
N/A | |
Completed |
NCT03022292 -
The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy
|
Phase 4 | |
Completed |
NCT02944227 -
Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration
|
Phase 4 | |
Terminated |
NCT03452527 -
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
|
Phase 2 | |
Completed |
NCT01243086 -
OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab
|
Phase 2 | |
Completed |
NCT03823300 -
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
|
Phase 3 | |
Recruiting |
NCT04420923 -
Optimizing the Treatment Strategy for Age-related Macular Degeneration
|
N/A |